アブストラクト
| Title | ARNI |
|---|---|
| Subtitle | 特集 Fantastic Four時代の心不全の治療戦略 心不全へのFantastic Fourの使い方 |
| Authors | 竹内一喬 |
| Authors (kana) | |
| Organization | 福井県済生会病院内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 9 |
| Page | 1739-1744 |
| Year/Month | 2023 / 7 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Points] ●ナトリウム利尿ペプチド系は心不全症例で保護的に働いている. ●ネプリライシン阻害作用によりナトリウム利尿ペプチドのほか, ブラジキニンなどが増加する. ●HFrEFでは予後改善効果が証明され, 薬物治療の中心的存在である. ●HFpEFでの効果は限定的だが, 強力な降圧作用が有効な場合がある. ●低血圧, 咳嗽, 血管浮腫などの副作用に留意が必要である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Sauer AJ, et al: Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev, 24:167-176, 2019
- 2) Mangiafico S, et al: Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J, 34:886-893c, 2013
- 3) Yamamoto K, et al: Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol, 273:H2406-2414, 1997
- 4) Kasama S, et al: Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J, 29:1485-1494, 2008
- 5) Volpe M, et al: The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci(Lond), 130:57-77, 2016
残りの12件を表示する
- 6) Levin ER, et al: Natriuretic peptides. N Engl J Med, 339:321-328, 1998
- 7) McMurray JJ, et al; PARADIGM-HF Investigators and Committees: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 371:993-1004, 2014
- 8) Solomon SD, et al; PARAGON-HF Investigators and Committees: Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med, 381:1609-1620, 2019
- 9) 日本循環器学会,他・編:2021年 JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. 2021
- 10) Tromp J, et al: A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail, 10:73-84, 2022
- 11) Velazquez EJ, et al; PIONEER-HF Investigators: Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med, 380:539-548, 2019
- 12) Mann DL, et al; LIFE Investigators: Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol, 7:17-25, 2022
- 13) McMurray JJV, et al: Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation, 141:338-351, 2020
- 14) Jackson AM, et al: Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J, 42:3741-3752, 2021
- 15) Du AX, et al: Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. J Cardiovasc Pharmacol, 73:149-154, 2019
- 16) Senni M, et al: Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail, 18:1193-1202, 2016
- 17) Kim H, et al: Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Sci Rep, 11:16335, 2021
